蜜桃传媒app

Leveraging genomics, proteomics, and other omics for drug target discovery in cardiometabolic diseases and complex traits: Toward better clinical care

Satoshi Yoshiji, McGill University
Tuesday September 17, 12-1pm
Zoom Link:听
In Person: 550 Sherbrooke, Room 189

Abstract:听
In this talk, I will cover three topics: (i) Leveraging large-scale genomics and proteomics to identify drug targets; (ii) Disentangling the genetic heterogeneity of type 2 diabetes; and (iii) A new multi-ancestry, multi-omics biobank of 12,500 individuals in Montreal.

First, I will describe our research that leverages large-scale genomics and proteomics to identify clinically actionable circulating proteins that link obesity to coronary artery disease, stroke, type 2 diabetes, and COVID-19. Specifically, I will explain how we identified circulating proteins that can be prioritized for drug development by integrating proteome-wide Mendelian randomization, colocalization, and single-cell RNA sequencing. I will also discuss our ongoing work to generate a multi-ancestry MR atlas of protein-disease associations, a project I have undertaken with QLS PhD student Chen-Yang Su and colleagues. Second, I will explain our efforts to disentangle the genetic heterogeneity of type 2 diabetes through a new Bayesian approach. Finally, I will describe a new multi-ancestry, multi-omics biobank of 12,500 individuals in Montreal, dedicated to drug target discovery and precision medicine, for which I serve as co-PI.

Short Bio:
Satoshi Yoshiji (pronounced 鈥測o-she-gee鈥�) is an Assistant Professor in the Department of Human Genetics and a board-certified endocrinologist. His research goal is to use genomics, proteomics, and other omics to identify drug targets and advance precision medicine for diabetes, obesity, cardiovascular diseases, and beyond. He is recruiting ambitious and forward-looking students. Webpage: